Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Board Comments on fine levied by the Exchange '.

Sebi PenaltyRegulatory & Legal View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹482.40

prior close

₹485.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-0.8% vs market

Pharmaceuticals peers, median of 148sector+0.3%-1.0% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+2.6

15m

+2.4

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.2-0.8+0.3-1.0

Next day

-0.4+0.2-0.6+0.3-0.7

+1.3+0.9+0.4+0.6+0.6

-2.2+0.1-2.2-0.3-1.8

-1.6+1.6-3.2+0.5-2.2

-0.6+2.8-3.4+0.6-1.1

-0.2+3.0-3.3+0.8-1.0

15d

-1.1+2.8-3.9+0.1-1.3

-4.6+3.1-7.7+1.5-6.1

-3.6+1.4-5.1-1.5-2.1

-9.2+1.4-10.6-4.2-5.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NSE and BSE had levied a fine on Akums Drugs and Pharmaceuticals for not following SEBI Listing Regulations 17(1) and 17(1A), which deal with the required composition of the Board of Directors. The company's Board met on August 8, 2025, to discuss this and stated that the delay was unintentional and a one-off issue caused by the late finalisation of a suitable independent director candidate. The company has since appointed an independent director, thereby fixing the non-compliance. A fine waiver application with supporting documents has already been submitted to NSE, and the Compliance Officer has attended a personal hearing; the NSE's decision on the waiver is still pending.

Likely market impact

This is a minor governance compliance issue with a relatively small regulatory fine, and the company has already remedied it by appointing the required independent director. Shareholders should watch for NSE's waiver decision; the matter is unlikely to materially affect the stock price but reflects a lapse in board composition timelines.